Regeneron Pharmaceuticals

MAIA Biotechnology reports favorable interim survival benefit for THIO in advanced NSCLC, with 16 patients surpassing 12-month follow-up, including 9 in third-line treatment achieving a median survival of 10.6 months, surpassing standard-of-care overall survival of 5.8 months. THIO followed by Libtayo® has been well-tolerated.

The Global Monoclonal Antibodies Market is projected to grow from USD 279.8 billion in 2024 to USD 804.7 billion by 2033, at a CAGR of 12.5%. North America is expected to dominate with a 47.5% share in 2024, driven by strong healthcare infrastructure and high R&D investments. Oncology is projected to lead the application segment with a 46.2% share. Major companies include Roche, Novartis, Johnson & Johnson, Pfizer, and Merck.

EMA approves Eylea 8 mg pre-filled syringe for nAMD and DME, offering efficient and precise treatment. Developed by Bayer and Regeneron, Eylea 8 mg extends treatment intervals up to five months with comparable efficacy and safety to Eylea 2 mg. The syringe aims to benefit ophthalmologists and patients with its simplicity and accuracy.

Despite declining use of Sanofi/Regeneron’s Dupixent due to competition from LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the overall population receiving advanced treatments for atopic dermatitis is rising, according to Spherix Global Insights. Dermatologists estimate that two-fifths of adult atopic dermatitis patients now receive advanced systemic treatments, highlighting the demand for effective AD treatments. The potential approvals of Galderma’s nemolizumab and Eli Lilly’s lebrikizumab could further shift physician preferences, with nemolizumab expected to gain more adoption than lebrikizumab.

Global Monoclonal Antibodies Market to reach USD 804.7 billion by 2033, growing at a CAGR of 12.5% from USD 279.8 billion in 2024. Dominated by North America, human-derived antibodies, and oncology applications, with key players including Roche, Novartis, and Johnson & Johnson.

Adding novel agents to perioperative durvalumab for NSCLC led to higher pCR and mPR rates compared to historical rates with durvalumab and chemotherapy. The highest response rates occurred with the addition of Dato-DXd (pCR 34.1%, mPR 65.9%). All combinations demonstrated manageable safety profiles and surgical rates comparable to approved regimens.

Dupixent's dominance in atopic dermatitis treatment is diminishing with the rise of competitors like Adbry, Cibinqo, and Rinvoq. Dermatologists anticipate adopting nemolizumab and lebrikizumab, further challenging Dupixent's market share.